Phase 2 N=47 A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients
Non-Small Cell Lung Cancer NSCLC
Primary: Overall Survival (OS) — 6.00 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=15 Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma
Malignant Mesothelioma (MPM)
Primary: Overall Response Rate — 2; 8; 1; 4 Participants
Phase 2 N=18 Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD)
Limb-Girdle Muscular Dystrophies · Facioscapulohumeral Muscular Dystrophy
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 4; 14; 0; 0 Participants
Phase 2 N=52 Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors
Solid Tumor, Adult
Primary: Immune-related Objective Response Rate — 9 Participants
Phase 2 N=8 Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular Dystrophy
Facioscapulohumeral Muscular Dystrophy (FSHD)
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 8; 0 Participants
Phase 2 N=15 Effectiveness of Onabotulinumtoxin A (Botox) in Pediatric Patients Experiencing Migraines: A Study in the Pediatric Pain Population
Migraine Disorders · Headache, Migraine · Pediatrics
Primary: Frequency of Migraines — 28; 20; 28 days — p=0.038
Phase 2 N=17 A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis
Dermatitis, Atopic
Primary: Mean Percentage Change From Baseline in EASI Score at Week 16 — -83.1; -92.3 Percentage change
Phase 2 N=83 Study to See How Well an Eye Drop, SURF-201, Works and What Side Effects There Are in Cataract Surgery Subjects
Post-surgical Ocular Inflammation · Post-surgical Ocular Pain
Primary: Anterior Chamber Cell (ACC) Grade: Number of Participants Achieving an ACC Grade of 0 — 22; 9 Participants — p=<0.001
Phase 2 N=3 A Clinical Trial of Endoscopic Surgery Followed by Chemotherapy and Proton Radiation for the Treatment of Tumors in the Sinus and Nasal Passages
Paranasal Sinus Cancer · Nasal Cavity Tumor · Nasal Cavity Adenocarcinoma
Primary: Local Control Assessment of Unresectable Paranasal Sinus and Nasal Cavity Tumors
Phase 2 N=11 Assessing Response to Inhaled Prostacyclin With Hyperpolarized Xe MRI
Pulmonary Vascular Disease
Primary: Percent Change in Abnormal RBC Percentage — -17.7 percent change
Phase 2 N=176 ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA
Age-related Macular Degeneration
Primary: LL BCVA Score Change From Baseline — 0.7; -0.6; 1.1; -0.8 Letters
Phase 2 N=46 Nicotinamide as an Early Alzheimer's Disease Treatment
Alzheimer's Disease · Mild Cognitive Impairment
Primary: Change in P-tau 231 — 4.71; 2.28 pg/ml — p=0.6096
Phase 2 N=87 Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer
Metastatic Bladder Urothelial Carcinoma · Metastatic Renal Pelvis and Ureter Urothelial Carcinoma · Metastatic Ureter Urothelial Carcinoma
Primary: Progression-free Survival (PFS) — 8.0; 8.0 Months
Phase 2 N=170 A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Participants Refractory to Conventional Therapy
Chronic Gout
Primary: Number of Participants With Serum Uric Acid (SUA) Reduction of < 6 mg/dL for at Least 80% of the Time — 44; 40 Participants — p=0.181
Phase 2 N=70 KPL-301 for Subjects With Giant Cell Arteritis
Giant Cell Arteritis
Primary: Time to Flare by Week 26 — NA; 25.1 weeks — p=0.0263